Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference

Ring Therapeutics®, a life sciences company pioneering a new class of targeted medicines, today announced new data on its Vector Conjugate platform and VectorBricks™ in vitro manufacturing technology.

Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments f…

Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...